Efficacy and Safety of 48 mg Talsaclidine (Free Base) Tid po (Panel 1) and 60 mg Talsaclidine (Free Base) Tid po (Panel 2) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Within Escalating Dose Panels in 150 Patients With Mild to Moderate Dementia of Alzheimer Type
Latest Information Update: 15 Oct 2014
At a glance
- Drugs Talsaclidine (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 15 Oct 2014 New trial record